1. Evaluation of BRAF Gene Status in Gliomas
- Author
-
Awadhesh Kumar Jaiswal, Sarita Agrawal, Sushila Jaiswal, Kuntal Kanti Das, Sanjay Behari, Swasti Tewari, Madam Mohan Godbole, and Prabhakar Misra
- Subjects
Oncology ,medicine.medical_specialty ,endocrine system diseases ,Pilocytic astrocytoma ,business.industry ,Significant difference ,Brain tumor ,Histology ,Who grade ,medicine.disease ,digestive system diseases ,Fusion gene ,Internal medicine ,Glioma ,medicine ,skin and connective tissue diseases ,business ,neoplasms ,Gene - Abstract
Background: Development of different molecular markers has given a new insight in the glioma management. KIAA1549-BRAF gene fusion has a diagnostic and prognostic significance. Aim: The aim of this study was to determine the KIAA1549-BRAF gene fusion in glioma and their correlation with various clinical parameters. Material and Methods: Forty cases of glioma were studied for KIAA1549-BRAF gene fusion by reverse transcription-PCR (RT-PCR). Results: Overall, KIAA1549-BRAF gene fusion was found in 22% (9/40) cases of glioma. Children had higher KIAA1549-BRAF fusion (72%; 8/11) as compared to adults (10%; 3/29) and this difference was statistically significant. Cerebellar location of tumor was significantly associated with KIAA1549-BRAF fusion. KIAA1549-BRAF fusion was highest in pilocytic astrocytoma (89%), and this difference was statistically significant. Statistically significant difference was noted between KIAA1549-BRAF fusion expression and WHO grade I glioma. Conclusion: Overall, KIAA1549-BRAF gene fusion was found in 22% (9/40) cases of glioma. Childhood age, pilocytic astrocytoma histology, cerebellar location and WHO grade I tumor were significantly associated with KIAA1549-BRAF gene fusion.
- Published
- 2021